BioTech Encyclopedia ⌂ Home

Liposomes and lipid nanoparticles: uses in research

Also: LNP, mRNA vaccines, liposomes

Liposomes are tiny fat bubbles that carry drugs. Lipid nanoparticles carry mRNA and made the COVID-19 mRNA vaccines possible.

Patents

Search Google Patents for this topic: all patents · recent applications (2022+)

Patent searches are generated from the topic's key terms; a patent is a legal claim, not proof that something works. See the Patents page.

Timeline

  1. 1965 First liposomes
  2. 2005 Modified mRNA
  3. 2013 Liposomal drugs
  4. 2020 mRNA vaccine trial
  5. 2021 Lipid nanoparticles for mRNA

Readiness: lab lab studies · prototype demonstrated objects · commercial products or buildings in real use · review summaries of other studies.
Export this topic's references: BibTeX · RIS (Zotero, EndNote, Mendeley)

Filter:

Start here

biomedical

lab biomedical 1965

First liposomes

Bangham and colleagues described swollen phospholipid layers, the first liposomes.

As reported in: Bangham, Standish, Watkins (1965). Diffusion of univalent ions across the lamellae of swollen phospholipids. Journal of Molecular Biology. doi:10.1016/S0022-2836(65)80093-6

Abstract only

review biomedical 2013

Liposomal drugs

Allen and Cullis reviewed liposomal drug delivery from concept to clinic.

Built / tested: liposomal drugs

As reported in: Allen, Cullis (2013). Liposomal drug delivery systems: From concept to clinical applications. Advanced Drug Delivery Reviews. doi:10.1016/j.addr.2012.09.037

Abstract only

lab biomedical 2005

Modified mRNA

Karikó and colleagues showed modified nucleosides help mRNA avoid immune detection, work honored with the 2023 Nobel Prize.

As reported in: Karikó, Buckstein, Ni et al. (2005). Suppression of RNA Recognition by Toll-like Receptors: The Impact of Nucleoside Modification and the Evolutionary Origin of RNA. Immunity. doi:10.1016/j.immuni.2005.06.008

Read free · publisher open access

commercial biomedical 2020

mRNA vaccine trial

Polack and colleagues reported the safety and efficacy trial of the BNT162b2 lipid-nanoparticle mRNA COVID-19 vaccine.

Built / tested: mRNA vaccine

As reported in: Polack, Thomas, Kitchin et al. (2020). Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. New England Journal of Medicine. doi:10.1056/NEJMoa2034577

Read free · preprint / author manuscript